Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw

Universiteit Gent

Katholieke Universiteit Leuven, Ku Leuven R&d

Vib Vzw

Karen Heyninck

Rudi Beyaert

Walter C Fiers

Peter Marynen

Thijs Baens

The present invention relates to inhibitors of MALT1 proteolytic and/or autoproteolytic activity. More specifically, it relates to compounds such as, but not limited to peptide derivates such as Z-LSSR-CHO (see SEQ ID NO:1), Z-LSSR-CMK (see SEQ ID NO:1), Z-GASR-CHO (see SEQ ID NO:2), and Z-GASR-CMK (see SEQ ID NO:2), and small compounds such as 5-{[5-(3-chloro-4-methylphenyl)-2-furyl]methylene}-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione and variants thereof, and the use of those compounds for the preparation of a medicament. The invention relates further to a method to screen for inhibitors of the MALT1 proteolytic and/or autoproteolytic activity.

Inhibitors of MALT1 proteolytic activity and uses thereof

The present invention relates to novel inhibitors of the Nuclear factor kappa B (NF-&#x3ba;B) activating pathway useful in the treatment of NF-&#x3ba;B related diseases and/or in the improvement of anti-tumor treatments. These inhibitors interfere early in the TRAF induced signaling pathway and are therefore more specific than I&#x3ba;B.

Inhibitors of NF-kappaB activation

The present invention relates to novel inhibitors of the Nuclear factor kappa B (NF-&kgr;B) activating pathway useful in the treatment of NF-&kgr;B related diseases and/or in the improvement of anti-tumor treatments. These inhibitors interfere early in the TRAF induced signaling pathway and are therefore more specific than I&kgr;B.

Inhibitors of NF-&kgr;B Activation

Growing community of inventors

Scheldewindeke, Belgium

Karen Heyninck